Adaptive Biotechnologies, the leader in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announced today that Chad Robins, President, Chief Executive Officer and Co-founder, will present during the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 4:00 p.m. PST in San Francisco, CA.

Mr. Robins will share an update on the Company’s milestone achievements from the past year, along with market opportunities and strategic objectives for its research, diagnostic and therapeutic business areas for 2016 and beyond.

About Adaptive Biotechnologies®

Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.